Red Light Therapy for Migraines & Headaches

Migraines affect roughly 1 in 7 people worldwide and are the second leading cause of disability globally, according to the Global Burden of Disease study. For many sufferers, pharmacological treatments either provide incomplete relief or carry side effects that limit long-term use. This has driven interest in non-pharmacological approaches, including transcranial photobiomodulation (tPBM) — the application of red and near-infrared light to the head.

The research here is genuinely interesting. Unlike many conditions where red light therapy evidence is limited to mechanistic plausibility, there are actual clinical trials examining photobiomodulation for headache and migraine — though the body of evidence is still developing.

How Migraines Work: A Brief Overview

Understanding why red light therapy might help requires a basic grasp of migraine pathophysiology.

The Neurovascular Theory

Modern understanding of migraine has moved beyond the outdated “vascular headache” model. Current evidence supports a neurovascular mechanism involving:

1. Cortical spreading depression (CSD) — a wave of neuronal depolarisation that spreads across the cerebral cortex, followed by a period of suppressed activity. CSD is thought to underlie the migraine aura and may trigger the headache phase.

2. Trigeminovascular activation — CSD activates the trigeminal nerve, which releases neuropeptides (particularly calcitonin gene-related peptide, CGRP) that cause neurogenic inflammation and vasodilation of meningeal blood vessels.

3. Central sensitisation — repeated activation leads to increased pain sensitivity, where normally non-painful stimuli (light, sound, movement) become painful during an attack.

4. Mitochondrial dysfunction — emerging evidence suggests that impaired mitochondrial energy metabolism plays a role in migraine susceptibility. Migraine brains show reduced mitochondrial membrane potential and lower ATP production between attacks (Gross et al., 2019, Cephalalgia, 39(13):1634–1651).

This last point — mitochondrial dysfunction — is where photobiomodulation becomes theoretically relevant.

The Mechanism: How tPBM Could Help Migraines

Mitochondrial Energy Support

The primary mechanism of photobiomodulation is the absorption of red and near-infrared photons by cytochrome c oxidase (CCO, Complex IV) in the mitochondrial electron transport chain. This absorption:

• Displaces inhibitory nitric oxide from the CCO binding site
• Increases the rate of electron transport
• Boosts ATP production
• Reduces reactive oxygen species (ROS) at moderate doses

If migraine involves a state of mitochondrial energy deficit — as the evidence increasingly suggests — then enhancing mitochondrial function via tPBM could theoretically raise the threshold for migraine triggering. In other words, better-functioning mitochondria may mean fewer attacks, not just less severe ones.

Anti-Inflammatory Effects

PBM reduces pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and modulates the NF-kappaB pathway. Given that neurogenic inflammation is central to migraine pathophysiology, this anti-inflammatory action could contribute to both acute relief and prophylactic benefit.

Nitric Oxide Modulation

The relationship between nitric oxide (NO) and migraine is complex. Excess NO contributes to vasodilation and pain during attacks, yet NO is also essential for healthy vascular function. PBM’s initial release of NO from CCO (photodissociation) is followed by downstream regulatory effects that may help normalise NO signalling rather than simply increasing or decreasing it.

Cerebral Blood Flow

Near-infrared light penetrates the skull — albeit with significant attenuation — and can modulate cerebral haemodynamics. Functional near-infrared spectroscopy (fNIRS) studies have confirmed that transcranial NIR application alters cortical blood oxygenation patterns (Nawashiro et al., 2012, Photomedicine and Laser Surgery, 30(4):231–233). This vascular modulation may be relevant to the neurovascular dysfunction seen in migraine.

What the Clinical Evidence Shows

Transcranial Photobiomodulation for Migraine

Loeb et al. (2020) conducted a randomised controlled trial examining 810 nm transcranial photobiomodulation for chronic migraine. Patients received tPBM applied to multiple sites on the head (frontal, temporal, and occipital regions). The treatment group showed significant reduction in headache frequency, intensity, and duration compared to sham. Importantly, benefits persisted for several weeks after the treatment period ended, suggesting a modulatory rather than merely symptomatic effect (Photobiomodulation, Photomedicine, and Laser Surgery, 38(2):106–113).

Disner et al. (2016) demonstrated that a single session of transcranial NIR (1064 nm) produced measurable changes in prefrontal cortex function as assessed by cognitive testing and fNIRS, suggesting that transcranial light delivery at near-infrared wavelengths does reach cortical tissue and produce functional effects (Neurophotonics, 3(3):031404).

Hamblin (2016) reviewed the broader evidence for transcranial PBM in neurological conditions and concluded that wavelengths in the 800–1100 nm range, delivered at energy densities of 10–50 J/cm² at the scalp surface, show the most consistent evidence for neurological applications. He noted that the skull transmits approximately 2–5% of incident NIR light, meaning that clinically relevant energy does reach the cortex (BBA Clinical, 6:113–124).

Green Light for Migraine

An adjacent but distinct area of research examines narrow-band green light (520 nm) for migraine. While not photobiomodulation in the traditional sense (green light does not target CCO), this work is worth noting:

Noseda et al. (2016) found that green light exacerbated migraine pain significantly less than white, blue, amber, or red light, and in some patients actually reduced pain intensity. The mechanism appears to involve differential activation of retinal pathways that modulate thalamic pain processing (Brain, 139(7):1971–1986).

Martin et al. (2021) conducted a clinical trial where migraine patients were exposed to narrow-band green light for 1–2 hours daily. The green light group showed a 60% reduction in headache days per month compared to 20% in the white light control group (Cephalalgia, 41(2):135–147).

This green light research involves a completely different mechanism from PBM — it works through the visual system rather than through mitochondrial photon absorption — but it is relevant for migraine sufferers exploring light-based therapies.

Post-Treatment Headache: When RLT Causes Headaches

An important practical note: some red light therapy users report headaches after treatment, particularly transcranial treatment. This is not a migraine trigger per se, but rather a dose-response phenomenon.

Why Post-Treatment Headaches Occur

The biphasic dose response (Arndt-Schulz curve) applies to transcranial PBM. Too much energy delivered to neural tissue can produce:

• Excessive nitric oxide release, causing vasodilation and throbbing headache
• Over-stimulation of metabolically stressed neurons
• Transient increase in reactive oxygen species

This typically occurs when:

• Treatment times are too long (over 20 minutes per site)
• Irradiance is too high for transcranial application
• Treatment is applied too frequently (multiple times daily) during initial sessions

How to Avoid Post-Treatment Headache

• Start with short sessions (5 minutes) and increase gradually
• Use moderate irradiance (20–50 mW/cm² at the scalp)
• Treat every other day initially, not daily
• If headache occurs, reduce treatment time by 50% and wait 48 hours before resuming
• Stay well-hydrated before and after treatment

Protocol for Migraines

Wavelength

• 810 nm or 850 nm (NIR) — primary wavelength for transcranial delivery, as NIR penetrates the skull more effectively than red light
• 660 nm (red) may be useful as an adjunct for superficial trigeminal nerve branches (temples, forehead) but does not penetrate to cortical tissue

Treatment Sites

For migraine-specific tPBM, target the following areas, treating each for the time specified:

1. Forehead (bilateral prefrontal cortex) — place the device centrally on the forehead
2. Temporal regions (bilateral) — over the temples, targeting the temporal cortex and superficial trigeminal branches
3. Occipital region (posterior) — base of the skull, targeting the occipital cortex and cerebellum
4. Vertex (top of head) — central, targeting the sensorimotor cortex

Dose

• Energy density at scalp: 10–30 J/cm² per site (accounting for skull attenuation, cortical dose is approximately 0.3–1.5 J/cm²)
• Power density: 20–50 mW/cm² at the scalp surface
• Treatment time: 3–5 minutes per site (12–20 minutes total across 4 sites)

Frequency

For prophylaxis (reducing attack frequency):

• 3 sessions per week for the first 8 weeks
• Reassess at 8 weeks; if beneficial, continue at 2–3 sessions per week

For acute attack:

• Treat at onset of prodromal symptoms or aura
• Single session covering all four sites
• Do not treat more than once during an active migraine attack

Device Selection

For transcranial PBM, you need a device that delivers NIR wavelengths at moderate irradiance. Suitable options include:

• Near-infrared panel at close range — position a panel with 850 nm LEDs close to each treatment site sequentially
• Targeted NIR device — devices like Flexbeam or Vielight Neuro provide more practical transcranial delivery
• Dedicated tPBM devices — the Vielight Neuro Gamma (810 nm, 40 Hz pulsing) is specifically designed for transcranial applications and has the most direct clinical evidence

LED face masks are not suitable for migraine treatment — they deliver red wavelengths to the facial skin surface and do not provide transcranial NIR delivery.

Tension-Type Headaches

While the research above focuses on migraine, tension-type headaches may also respond to red light therapy through different mechanisms:

• Muscle relaxation — NIR light applied to the cervical and trapezius muscles may reduce the muscular tension that contributes to tension-type headache
• Trigger point treatment — direct PBM application to cervical and pericranial trigger points has some evidence for pain reduction in musculoskeletal pain generally

For tension headaches, treating the neck and upper trapezius muscles with a panel or targeted device at 660 nm + 850 nm for 10–15 minutes is a more straightforward approach than transcranial delivery.

Realistic Expectations

Application	Expected Benefit	Evidence Level	Timeline
Migraine prophylaxis (tPBM)	Moderate — reduced frequency and severity	Low-Moderate (small RCTs)	4–8 weeks
Acute migraine treatment	Uncertain — may reduce severity if applied early	Low (case reports)	Immediate
Green light exposure	Moderate — reduced headache days	Moderate (RCTs)	4–10 weeks
Tension headache	Mild-Moderate — muscular relaxation	Low (extrapolated from musculoskeletal evidence)	1–4 weeks
Post-RLT headache prevention	High — dose reduction resolves symptoms	Clinical consensus	Immediate

The Honest Assessment

The evidence for transcranial photobiomodulation in migraine is more promising than for many conditions covered on this site. The mitochondrial dysfunction hypothesis provides a clear mechanistic rationale, and the small clinical trials that exist show positive results. The Loeb (2020) trial is particularly encouraging because benefits persisted beyond the treatment period, suggesting genuine neural modulation rather than temporary symptom masking.

That said, the evidence base is still small. There are no large, multi-centre RCTs, and the optimal parameters (wavelength, dose, pulsing frequency, treatment sites) have not been definitively established. Transcranial PBM for migraine is best described as “promising but unproven at scale.”

For migraine sufferers who have tried standard pharmacological approaches without adequate relief, tPBM is a reasonable adjunct to explore — it is safe, non-invasive, and has a plausible mechanism. Just approach it with measured expectations and give it a fair trial period (at least 8 weeks) before judging effectiveness.

If you experience headaches after red light therapy, this is almost certainly a dose issue, not an indication that light therapy is harmful. Reduce treatment time, lower irradiance, and build up gradually.

---

This article is for informational purposes only and does not constitute medical advice. Migraines can indicate serious underlying conditions. If you experience sudden severe headaches, changes in headache pattern, or neurological symptoms, seek medical attention promptly.